NasdaqGS:NTRABiotechs
Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)
Natera, Inc. recently reported Clinical Cancer Research data showing its Signatera molecular residual disease test helped older women with early-stage ER+/HER2- breast cancer use primary endocrine therapy instead of surgery, with testing done at baseline and then every 3–6 months.
The study’s ability to identify patients who remained progression-free and to detect molecular signs of tumor progression before imaging highlights Signatera’s potential role in personalized treatment decisions for...